The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B‐cell lymphoma

Haixiang Pei; Yihua Chen

doi:10.1002/ctd2.56

Clinical and Translational Discovery (Jun 2022)

The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B‐cell lymphoma

Haixiang Pei,
Yihua Chen

Affiliations

Haixiang Pei: Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences, School of Life Sciences East China Normal University Shanghai China
Yihua Chen: Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences, School of Life Sciences East China Normal University Shanghai China

DOI: https://doi.org/10.1002/ctd2.56
Journal volume & issue: Vol. 2, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Single histone deacetylases inhibitors (HDACis) or current combination therapies show limited clinical efficiency in facing the striking heterogeneity of diffuse large B‐cell lymphoma (DLBCL). This commentary reviews the research conducted by Wang et al. to demonstrate the mechanism of the highly efficient HDACi LAQ824 and a promising HDCAi‐based combination therapy approach in DLBCL.

Published in Clinical and Translational Discovery

ISSN: 2768-0622 (Online)
Publisher: Wiley
Country of publisher: Australia
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://onlinelibrary.wiley.com/journal/27680622

About the journal

Abstract

Keywords